

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/31, A61K 39/106, C07K 14/28, I4/245	A1	(11) International Publication Number: WO 97/02348 (43) International Publication Date: 23 January 1997 (23.01.97)
(21) International Application Number: PCT/IB96/00703 (22) International Filing Date: 1 July 1996 (01.07.96) (30) Priority Data: 9513371.6 30 June 1995 (30.06.95) GB (71) Applicant (for all designated States except US): BIOCINE S.P.A. [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): PIZZA, Mariagrazia [IT/IT]; Strada di Montalbucco, 160, I-53100 Siena (IT). FONTANA, Maria, Rita [IT/IT]; Via del Colle, 19, I-53100 Siena (IT). GIANNELLI, Valentina [IT/IT]; Via Corsano Grotti, 26, Ville di Corsano, I-53014 Monteroni d'Arbia (IT). RAPPUOLI, Rino [IT/IT]; Via Calamandrei, 39, Quercegrossa, I-53010 Monteriggioni (IT). (74) Agent: HALLYBONE, Huw, George; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: IMMUNOGENIC DETOXIFIED MUTANTS OF CHOLERA TOXIN (57) Abstract An immunogenic detoxified protein comprising the amino acid sequence of subunit A of a cholera toxin (CT-A) or a fragment thereof or the amino acid sequence of subunit A of an <i>Escherichia coli</i> heat labile toxin (LT-A) or a fragment thereof wherein the amino acids at, or in positions corresponding to Ser-63 and Arg-192 are replaced with another amino acid. The immunogenic detoxified protein is useful as vaccine for <i>Vibrio cholerae</i> or an enterotoxigenic strain of <i>Escherichia coli</i> and is produced by recombinant DNA means by site-directed mutagenesis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

IMMUNOGENIC DETOXIFIED MUTANTS OF CHOLERA TOXIN

Field of the invention

5 The present invention relates to immunogenic detoxified proteins of cholera toxins (CT), or of heat labile toxins (LT) produced by the enterotoxigenic strains of *Escherichia coli* (*E.coli*) wherein the amino acids at, or in positions corresponding to, Ser-63 and Arg-192 are replaced with
10 another amino acid and to their use in vaccines which are useful for the prevention or treatment of cholera or enterotoxigenic *E.Coli* infections and as mucosal adjuvants for other immunogenic proteins. The detoxified immunogenic proteins can be suitably produced using recombinant DNA
15 techniques by site-directed mutagenesis of DNA encoding the wild type toxins.

Background to the Invention

20 Cholera is a contagious disease widely distributed in the world, in particular in the Third World, where, in certain areas, it is endemic. The serious disorders which develop in the intestinal system prove fatal in a high percentage of the recorded cases of the disease.

25

The etiological agent of cholera is the Gram-negative microorganism *Vibrio cholerae* (*V.cholerae*). This colonises the intestinal tract of individuals who have come into contact with it through ingestion of contaminated food or
30 water, and multiplies to very high concentrations. The principal symptom is severe diarrhoea as a result of which the patient can lose as much as 10-15 litres of liquids per day via the faeces. As a result of the severe dehydration and loss of electrolytes, the patient does not withstand the
35 infection in 50-60% of cases, and dies. The diarrhoea caused by *V.cholerae* is due to the secretion of cholera toxin, CT, which acts by stimulating the activity of the adenylate cyclase enzyme so as to induce disturbances at cell level.

SUBSTITUTE SHEET (RULE 26)

Although cholera can be effectively cured by controlled and intense rehydration, the distribution of a vaccine is desirable with a view to complete control and future
5 eradication of the disease.

At the present time, there exists a vaccination against cholera, consisting of parenteral administration of killed bacteria. Although some countries insist on vaccination
10 against the disease, there are serious doubts as to its real usefulness, given that the current cellular vaccine protects against the consequences of the infection in only 50% of the cases and that the protection is also extremely limited in duration, to less than 6 months.

15

In Bangladesh, an experimental trial is in progress (1990-92) of an oral vaccine consisting of killed bacteria with the addition of subunit B of cholera toxin, which is known to be highly immunogenic. This product succeeds in inducing
20 lasting protection, without special side effects (Holmgren J., Clemens J., Sack DA., Sanchez J. and Svennerholm AM; "Oral Immunization against cholera" Curr. Top. Microbiol. Immunol. (1988), 146, 197-204).

25 Cholera toxin resembles the heat labile toxins of enterotoxigenic strains of Escherichia coli in amino acid sequence, structure and mode of action.

The consequences of infection with an enterotoxigenic strain
30 of E.coli are similar to, though less serious than, those of cholera, and consist of severe diarrhoea and intestinal disorders.

The CT and LT toxins all comprise a single A subunit (or
35 protomer A) responsible for the enzymic activity of the toxin (herein CT-A or LT-A) and five identical B subunits (or protomer B) which are involved in the binding of the toxin to the intestinal epithelial cells (herein CT-B or LT-

Various groups have attempted to identify mutations of the genes, which involve loss of the toxicity characteristics of the encoded proteins. The studies are predominantly being
5 carried out in respect of the gene for the toxin LT, from *E. coli*.

Harford, S. et al (Eur. J. Biochem. 183, page 311 (1989)) describe the production of a toxoid by *in vitro* mutagenesis
10 of the LT-A gene from *E. coli* pathogenic for pigs. The resulting successful mutation contained a Ser-61-Phe substitution and a Gly-79-Lys substitution, the former being considered the more important. Harford et al suggest that, because of the similarities between the LT-A genes in *E. coli*
15 pathogenic to humans and pigs and the CT-A gene, and because the toxins are thought to operate by a common mechanism, it may be possible to produce a cholera holotoxoid by introducing the Ser-61-Phe mutation into the CT-A gene.

20 Tsuji, T. et al (J. Biol. Chem. 265, p. 22520 (1990)) describe the mutation of the LT-A gene from plasmid EWD299 to produce a single substitution Glu-112-Lys which affects the toxicity of the mutant LT yet does not change the immunogenicity of the protein.

25 Grant, C.C.R. et al (Abstract B289 of the 92nd General Meeting of the American Society for Microbiology, 26-30th May 1992) describe conservative substitutions of histidines at 44 and 70 and tryptophan at 127 in LT-A which result in
30 significant reductions in enzymic activity.

Some work has been conducted on mutations to CT.

35 Kaslow, H.R. et al (Abstract B291 of the 92nd General Meeting of the American Society for Microbiology, 26-30th May 1992) describe mutating Asp-1 and His-44 and truncating after amino acid 180 in CT-A which all essentially eliminate activity. Mutating Arg-9 is said to markedly attenuate

B).

The A subunit penetrates the cell membrane and causes activation of adenylate cyclase by NAD-dependent ADP-
5 ribosylation of a GTP-binding protein which controls the activity of the enzyme. The clinical effect of this is to cause massive fluid loss into the intestine.

Considerable research has been conducted on cholera toxin
10 and the *E. coli* heat labile toxins.

The sequence of CT is known and has been described (Mekalanos J.J. et al Nature 306, page 551 (1983)).

15 The sequence of LT from enterotoxigenic strains of *E. coli* is, as mentioned, 80% homologous to CT and it too is known and described in the scientific literature. Spicer E.K. et al (Biol. Chem. 257 p. 5716-5721 (1982)) describe the amino acid sequence of the A sub unit of the heat labile toxin
20 from an enterotoxigenic strain of *E. coli* found in pigs.

A bacterial chromosomal form of LT has been identified and sequenced by Pickett C.L. et al (J. Bacteriol. 169, 5180-5187, (1987)).

25

The sequence of the A subunit of LT from a strain of *E. coli* known to affect humans has also been sequenced (Yamamoto et al, J. Biol. Chem., 259, 5037-5044, (1984)).

30 In view of the potential clinical significance of a vaccine against cholera and enterotoxigenic bacteria there is a continuing and great interest in producing a detoxified toxin capable of immunising against cholera and enterotoxigenic bacteria. The techniques of genetic
35 engineering allow specific mutations to be introduced into the genes encoding the toxins and the production of the mutated toxins using now conventional techniques of gene expression and protein purification.

activity. Mutating other amino acid sites had little effect on toxicity.

Burnette, W.N. et al (Inf. and Immun. 59(11), 4266-4270, 5 (1991)) describe site-specific mutagenesis of CT-A to produce an Arg-7-Lys mutation paralleling that of a known detoxifying mutation in the A subunit of the *Bordetella pertussis* toxin. The mutation resulted in the complete abolition of detectable ADP-ribosyltransferase activity.

10

International patent application WO 92/19265 (Burnette, Kaslow and Amgen Inc.) describes mutations of CT-A at Arg-7, Asp-9, Arg-11, His-44, His-70 and Glu-112.

15 Mutations at Glu-110 (LT and CT) and Arg-146 (LT) have also been described in the literature (Lobet, Inf. Immun., 2870, 1991; Lai, Biochem. Biophys. Res. Comm. 341 1983; Okamoto J. Bacteriol. 2208, 1988).

20 The crystal structure of LT has been determined by Sixma et al (Nature, 351, 371-377, May 1991) and confirms the mutagenesis results described earlier in the literature, explaining structurally the significance of Glu-112 and Ser-61 in activity of the A sub unit and suggesting that His-
25 44, Ser-114 and Arg-54 which are in the immediate neighbourhood may be important for catalysis or recognition.

It is known that the development of toxicity of the A subunits of CT and LT requires proteolytic cleavage of A1
30 and A2 subunits at around amino acid Arg-192 (Grant et al Inf. & Immun. (1994) 62(10) 4270-4278).

Immunogenic detoxified proteins comprising the amino acid sequence of subunit A of a cholera toxin (CT-A) or a
35 fragment thereof or subunit A of an *Escherichia coli* heat labile toxin (LT-A) or a fragment thereof, wherein one or more amino acids at, or in positions corresponding to Val-53, Ser-63, Val-97, Tyr-104 or Pro-106 are replaced with

another amino acid are disclosed in WO 93/13202 (Biocine Sclavo SpA). Optionally the amino acid sequence may include other mutations such as, for example, substitutions at one or more of Arg-7, Asp-9, Arg-11, His-44, Arg-54, Ser-61, 5 His-70, His-107, Glu-110, Glu-112, Ser-114, Trp-127, Arg-146 or Arg-192.

Detoxified mutants of pertussis toxin have been reported to be useful both for direct intranasal vaccination and as a 10 mucosal adjuvant for other vaccines (Roberts et al Inf. & Immun. (1995) 63(6) 2100-2108). Published International patent application WO 95/17211 (Biocine SpA) describes the use of detoxified mutants of CT and LT as mucosal adjuvants.

15 Summary of the invention

We have discovered that a double mutation of the CT or LT amino acid sequence results in a immunogenic detoxified protein with improved stability characteristics. Although 20 we have previously shown that mutation at Ser-63 detoxifies CT and LT, further experiments have shown, unexpectedly that mutation around the Arg-192 position markedly improves the stability of the resulting protein. Protein stability is a critical factor in the design of active agents for use in 25 vaccines since the half-life of such an agent correlates with the efficacy of the vaccine. Longer lived agents provide better vaccination offering the possibility of reducing the need for adjuvants or even shortening the vaccination regimen. Similarly, stability affects the 30 efficacy of an active agent present in a composition for its adjuvant activity.

According the present invention, there is provided an immunogenic detoxified protein comprising the amino acid 35 sequence of subunit A of a cholera toxin (CT-A) or a fragment thereof or the amino acid sequence of subunit A of an *Escherichia coli* heat labile toxin (LT-A) or a fragment thereof wherein the amino acids at, or in positions

corresponding to, Ser-63 and Arg-192 are replaced with another amino acid.

5 In this specification, references to CT and LT encompass the various naturally occurring strain variants as well other variants encompassing changes from the sequences disclosed herein which do not affect the immunogenicity of the assembled toxoid.

10 The amino acid sequences for CT and LT are definitively described in Domenighini et al Molecular Microbiology (1995) 15(6) 1165-1167.

15 The amino acid substituted for the wild type amino acid may be a naturally occurring amino acid or may be a modified or synthetic amino acid, provided that the mutant retains the necessary immunogenic properties and exhibits a substantially reduced toxicity. The substitution may involve deletion of an amino acid.

20

Substitutions which alter the amphotericity and hydrophilicity whilst retaining the steric effect of the substituting amino acid as far as possible are generally preferred.

25

As used herein, the term "detoxified" means that the immunogenic composition exhibits a substantially lower toxicity relative to its naturally occurring toxin counterpart. The substantially lower toxicity should be 30 sufficiently low for the protein to be used in an immunogenic composition in an immunologically effective amount as a vaccine with causing significant side effects. For example, the immunogenic detoxified protein should have a toxicity of less than 0.01% of the naturally occurring 35 toxin counterpart. The toxicity may be measured in mouse CHO cells or preferably by evaluation of the morphological changes induced in Y1 cells. The term "toxoid" means a genetically detoxified toxin.

SUBSTITUTE SHEET (RULE 26)

The immunogenic protein may be a CT or LT subunit A toxoid, but is preferably an assembled toxin molecule comprising a mutated CT-A or LT-A subunit and five B subunits of CT or
5 LT. The B subunit may be a naturally occurring subunit or may itself be mutated.

The immunogenic protein is preferably a naturally occurring CT-A or an LT-A suitably modified as described above.
10 However, conservative amino acid changes may be made which do not affect the immunogenicity or the toxicity of immunogenic protein and preferably do not affect the ability of the immunogenic protein to form complete toxin with B subunit protein. Also, the immunogenic protein may be a
15 fragment of CT-A or an LT-A provided that the fragment is immunogenic and non toxic and contains at least one of the conserved regions containing one of the mutations according to the invention.

20 Both positions Ser-63 and Arg-192 are modified in the detoxified protein of the invention. Preferably, Ser-63 is replaced with Lys-63. Preferably Arg-192 is replaced with Asn-192 or Gly-192. Most preferably Ser-63 is replaced with Lys-63 and Arg-192 is replaced with Asn-192 or Gly-192.

25 According to a second aspect of the invention, there is provided an immunogenic composition for use as a vaccine comprising an immunogenic detoxified protein of the first aspect of the invention and a pharmaceutically acceptable
30 carrier.

The invention also provides a vaccine composition comprising an immunogenic detoxified protein according to the first aspect of the invention and a pharmaceutically acceptable
35 carrier. The vaccine composition may further comprise an adjuvant. Alternatively, the vaccine composition may comprise a second antigen capable of raising an immunological response to another disease. In such an

alternative composition, the immunogenic detoxified protein acts as a mucosal adjuvant.

According to a third aspect of the invention, there is
5 provided a method of vaccinating a mammal against *Vibrio cholerae* or an enterotoxigenic strain of *Escherichia coli* comprising administering an immunologically effective amount of an immunogenic detoxified protein according to the first aspect of the invention. Optionally, the immunogenic
10 detoxified protein of the invention may act as an adjuvant for a second immunogenic protein administered separately, sequentially or with the immunogenic detoxified protein of the invention.

15 The immunogenic detoxified proteins of the invention may be synthesised chemically using conventional peptide synthesis techniques, but are preferably produced by recombinant DNA means.

20 According to a fourth aspect of the invention there is provided a DNA sequence encoding an immunogenic detoxified protein according to the first aspect of the invention.

Preferably the DNA sequence contains a DNA sequence encoding
25 a complete CT or LT comprising DNA encoding both the detoxified subunit A and subunit B in a polycistronic unit. Alternatively, the DNA may encode only the detoxified subunit A.

30 According to a fifth aspect of the invention, there is provided a vector carrying a DNA according to the fourth aspect of the invention.

According to a sixth aspect of the invention, there is
35 provided a host cell line transformed with the vector according to the fifth aspect of the invention.

The host cell may be any host capable of producing CT or LT

SUBSTITUTE SHEET (RULE 26)

but is preferably a bacterium, most suitably *E.coli* or *V.cholerae* suitably engineered to produce the desired immunogenic detoxified protein.

5 In a further embodiment of the sixth aspect of the invention, the host cell may itself provide a protective species, for example an *E.coli* or *V.cholerae* strain mutated to a phenotype lacking wild type LT or CT and carrying and expressing an immunogenic detoxified protein of the first
10 aspect of the invention.

In a further embodiment of the sixth aspect of the invention the host cell is capable of expressing a chromosomal LT-A gene according to the first aspect of the invention.

15

According to a seventh aspect of the invention, there is provided a process for the production of an immunogenic detoxified protein according to the first aspect of the invention comprising culturing a host cell according to the
20 sixth aspect of the invention.

According to a eighth aspect of the invention there is provided a process for the production of DNA according to the fourth aspect of the invention comprising the steps of
25 subjecting a DNA encoding a CT-A or an LT-A or a fragment thereof to site-directed mutagenesis.

According to a ninth aspect of the invention there is provided a process for the formulation of a vaccine
30 comprising bringing an immunogenic detoxified protein according to the first aspect of the invention into association with a pharmaceutically acceptable carrier and optionally with an adjuvant.

35 Industrial Applicability

The immunogenic detoxified protein of the invention constitutes the active component of a vaccine composition

SUBSTITUTE SHEET (RULE 26)

useful for the prevention and treatment of cholera infections or infections by enterotoxigenic strains of *E.coli*. The immunogenic detoxified protein may also be used in a vaccine composition as a mucosal adjuvant. The
5 compositions are thus applicable for use in the pharmaceutical industry.

Brief Description of the Drawings

10 Fig.1 Western blot of periplasmic extracts of *E.coli* TG1 strains expressing wild-type LT, LTG192 or LTK63/G192 mutants, showing the A and B subunits. Purified LTK63 has been used as control.

15 Fig. 2 Western blot of purified wild-type LT and LTK63, LTG192, LTK63/G192 mutants treated with trypsin at 37°C at the initial time, after 15, 30 and 90 minutes, respectively. (Toxin-trypsin ratio is 1:100, incubation buffer TEAN pH 7.5).

20

Fig. 3 Western blot of purified wild-type LT and LTK63, LTG192, LTK63/G192 mutants treated with trypsin at the initial time, after 5, 15, 30, 45, 60 minutes, respectively. (Toxin-trypsin ratio 1:100, incubation buffer TEAN pH
25 7.5+3.5M urea.)

Fig. 4 Western blot of purified LTN192 mutant treated with trypsin at the initial time, 5, 15, 30, 45, 60 minutes, respectively. (Toxin-trypsin ratio 1:100, incubation buffer
30 TEAN pH 7.5+3.5M urea).

Fig. 5 Titers of anti-LT IgG in the sera of mice after 36 days of immunization with 1µg of LTK63 and LTK63/G192, respectively. Four mice from each group were immunized i.n.
35 with LTK63 or LTK63/G192. Sera of each group were pooled and samples tested. Titers were determined as the reciprocal of dilution corresponding to OD₄₅₀=0.3.

Fig. 6 Western blot showing the expression in *E. coli* of CT and LT mutants into the proteolytic loop and analysis of resistance to trypsin treatment. Lane 1, 2, 3, 4, 5, 6, 7, periplasmic extract of *E. coli* expressing LT and CT mutants 5 treated with 13.5 µg /ml of trypsin at 37° C for 15 min. Lane 8, CT purified. Lane 9, 10, 11, 12, 13, 14, 15, periplasmic extract of *E. coli* expressing CT and LT mutants untreated. An uncleaved A subunit of LT and CT molecule; A1, cleaved A subunit; Bm, B monomer.

10

Fig. 7 Western blot showing the expression in O395 *V. cholerae* strain of CT and LT mutants into the proteolytic loop to test the resistance at the specific protease (hemagglutinin /protease). Lane 1, LT purified. Lane 2, 3, 15 4, supernatant of *V. cholerae* O395 expressing LT mutants. Lane 5, CT purified. Lane 6, 7, 8, 9, supernatant of *V. cholerae* O395 expressing CT mutants. An uncleaved A subunit of LT and CT molecule; A1, cleaved A subunit; Bm, B monomer.

20 Detailed Description of Embodiments of the Invention

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, 25 which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Sambrook, et al., MOLECULAR CLONING; A LABORATORY MANUAL, SECOND EDITION (1989); DNA CLONING, VOLUMES I AND II (D.N Glover ed. 1985); OLIGONUCLEOTIDE SYNTHESIS (M.J. Gait ed, 1984); 30 NUCLEIC ACID HYBRIDIZATION (B.D. Hames & S.J. Higgins eds. 1984); TRANSCRIPTION AND TRANSLATION (B.D. Hames & S.J. Higgins eds. 1984); ANIMAL CELL CULTURE (R.I. Freshney ed. 1986); IMMOBILIZED CELLS AND ENZYMES (IRL Press, 1986); B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING (1984); the 35 series, METHODS IN ENZYMOLOGY (Academic Press, Inc.); GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu,

eds., respectively), Mayer and Walker, eds. (1987), IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY (Academic Press, London), Scopes, (1987), PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, Second Edition 5 (Springer-Verlag, N.Y.), and HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, VOLUMES I-IV (D.M. Weir and C. C. Blackwell eds 1986).

Standard abbreviations for nucleotides and amino acids are 10 used in this specification. All publications, patents, and patent applications cited herein are incorporated by reference.

In particular, the following amino acid abbreviations are 15 used:

	Alanine	A	Ala
	Arginine	R	Arg
	Asparagine	N	Asn
<u>20</u>	Aspartic Acid	D	Asp
	Cysteine	C	Cys
	Glycine	G	Gly
	Glutamic Acid	E	Glu
	Glutamine	Q	Gln
<u>25</u>	Histidine	H	His
	Isoleucine	I	Ile
	Leucine	L	Leu
	Lysine	K	Lys
	Methionine	M	Met
<u>30</u>	Phenylalanine	F	Phe
	Proline	P	Pro
	Serine	S	Ser
	Threonine	T	Thr
	Tryptophan	W	Trp
<u>35</u>	Tyrosine	Y	Tyr
	Valine	V	Val

As mentioned above examples of the immunogenic detoxified

SUBSTITUTE SHEET (RULE 26)

protein that can be used in the present invention include polypeptides with minor amino acid variations from the natural amino acid sequence of the protein other than at the sites of mutation specifically mentioned.

5

A significant advantage of producing the immunogenic detoxified protein by recombinant DNA techniques rather than by isolating and purifying a protein from natural sources is that equivalent quantities of the protein can be produced by
10 using less starting material than would be required for isolating the protein from a natural source. Producing the protein by recombinant techniques also permits the protein to be isolated in the absence of some molecules normally present in cells. Indeed, protein compositions entirely
15 free of any trace of human protein contaminants can readily be produced because the only human protein produced by the recombinant non-human host is the recombinant protein at issue. Potential viral agents from natural sources and viral components pathogenic to humans are also avoided.
20 Also, genetically detoxified toxin are less likely to revert to a toxic form than more traditional, chemically detoxified toxins.

Pharmaceutically acceptable carriers include any carrier
25 that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid
30 copolymers, lipid aggregates (such as oil droplets or liposomes) and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents (adjuvants).

35

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: aluminum salts (alum) such as aluminium hydroxide, aluminium phosphate,

pharmaceutically acceptable carrier and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and 5 the like, may be present in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, 10 liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect as discussed above under pharmaceutically acceptable carriers.

15 Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount 20 to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g., nonhuman primate, 25 primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in 30 a relatively broad range that can be determined through routine trials.

The immunogenic compositions are conventionally administered parenterally, e.g. by injection either subcutaneously or 35 intramuscularly. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories and transdermal applications. Dosage treatment may be a single dose schedule or a multiple

aluminium sulfate etc., oil emulsion formulations, with or without other specific immunostimulating agents such as muramyl peptides or bacterial cell wall components, such as for example (1) MF59 (Published International patent application WO-A-90/14837, containing 5% Squalene, 0.5% Tween® 80, 0.5% Span® 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA 02164), (2) SAF, containing 10% squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (3) RIBI™ adjuvant system (RAS) (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween® 80 and one or more bacterial cell wall components from the group consisting of monophosphoryl lipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS) preferably MPL+CWS (Detox™), muramyl peptides such as N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE) etc., and cytokines, such as interleukins (IL-1, IL-2 etc) macrophage colony stimulating factor (M-CSF), tumour necrosis factor (TNF) etc. Additionally, saponin adjuvants, such as Stimulon™ (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMS (immunostimulating complexes). Furthermore, Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA) may be used. Alum and MF59 are preferred.

The immunogenic detoxified protein of the invention may be used as an adjuvant for a second antigen in an immunologically active composition for the treatment or vaccination of the human or animal body.

The immunogenic compositions (e.g. the antigen,

dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

The term "recombinant polynucleotide" as used herein intends
5 a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is
10 linked in nature, or (3) does not occur in nature.

The term "polynucleotide" as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers
15 only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA and RNA. It also includes known types of modifications, for example, labels which are known in the art, methylation, "caps", substitution of one or more of the naturally occurring
20 nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those
25 containing pendant moieties, such as, for example proteins (including for e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals,
30 etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide.

A "replicon" is any genetic element, e.g., a plasmid, a
35 chromosome, a virus, a cosmid, etc. that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control. This may include selectable markers.

A "vector" is a replicon in which another polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment.

5

"Control sequence" refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in 10 prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term "control sequences" is intended to 15 include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

20 "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is 25 achieved under conditions compatible with the control sequences.

An "open reading frame" (ORF) is a region of a polynucleotide sequence which encodes a polypeptide; this 30 region may represent a portion of a coding sequence or a total coding sequence.

A "coding sequence" is a polynucleotide sequence which is translated into a polypeptide, usually via mRNA, when placed 35 under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can

include, but is not limited to, cDNA, and recombinant polynucleotide sequences.

"PCR" refers to the technique of polymerase chain reaction
5 as described in Saiki, et al., Nature 324:163 (1986); and
Scharf et al., Science (1986) 233:1076-1078; and U.S.
4,683,195; and U.S. 4,683,202.

As used herein, x is "heterologous" with respect to y if x
10 is not naturally associated with y in the identical manner;
i.e., x is not associated with y in nature or x is not
associated with y in the same manner as is found in nature.

"Homology" refers to the degree of similarity between x and
15 y. The correspondence between the sequence from one form to
another can be determined by techniques known in the art.
For example, they can be determined by a direct comparison
of the sequence information of the polynucleotide.
Alternatively, homology can be determined by hybridization
20 of the polynucleotides under conditions which form stable
duplexes between homologous regions (for example, those
which would be used prior to S_1 digestion), followed by
digestion with single-stranded specific nuclease(s), fol-
lowed by size determination of the digested fragments.

25 As used herein, the term "polypeptide" refers to a polymer
of amino acids and does not refer to a specific length of
the product; thus, peptides, oligopeptides, and proteins are
included within the definition of polypeptide. This term
30 also does not refer to or exclude post expression
modifications of the polypeptide, for example,
glycosylations, acetylations, phosphorylations and the like.
Included within the definition are, for example,
polypeptides containing one or more analogs of an amino acid
35 (including, for example, unnatural amino acids, etc.),
polypeptides with substituted linkages, as well as other
modifications known in the art, both naturally occurring and
non-naturally occurring.

A polypeptide or amino acid sequence "derived from" a designated nucleic acid sequence refers to a polypeptide having an amino acid sequence identical to that of a
5 polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 3-5 amino acids, and more preferably at least 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which is immunologically identifiable with a polypeptide encoded in the
10 sequence. This terminology also includes a polypeptide expressed from a designated nucleic acid sequence.

The protein may be used for producing antibodies, either monoclonal or polyclonal, specific to the protein. The
15 methods for producing these antibodies are known in the art.

"Recombinant host cells", "host cells," "cells," "cell cultures," and other such terms denote, for example, microorganisms, insect cells, and mammalian cells, that can
20 be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transformed. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in
25 genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation. Examples for mammalian host cells include Chinese hamster ovary (CHO) and monkey kidney (COS) cells.

30 Specifically, as used herein, "cell line," refers to a population of cells capable of continuous or prolonged growth and division in vitro. Often, cell lines are clonal populations derived from a single progenitor cell. It is further known in the art that spontaneous or induced changes
35 can occur in karyotype during storage or transfer of such clonal populations. Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or cultures, and the cell line referred to

includes such variants. The term "cell lines" also includes immortalized cells. Preferably, cell lines include nonhybrid cell lines or hybridomas to only two cell types.

- 5 As used herein, the term "microorganism" includes prokaryotic and eukaryotic microbial species such as bacteria and fungi, the latter including yeast and filamentous fungi.
- 10 "Transformation", as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation. The exogenous polynucleotide may be maintained as a
- 15 non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.

By "genomic" is meant a collection or library of DNA molecules which are derived from restriction fragments that

20 have been cloned in vectors. This may include all or part of the genetic material of an organism.

By "cDNA" is meant a complementary DNA sequence that hybridizes to a complementary strand of DNA.

- 25
- By "purified" and "isolated" is meant, when referring to a polypeptide or nucleotide sequence, that the indicated molecule is present in the substantial absence of other biological macromolecules of the same type. The term
- 30 "purified" as used herein preferably means at least 75% by weight, more preferably at least 85% by weight, more preferably still at least 95% by weight, and most preferably at least 98% by weight, of biological macromolecules of the same type present (but water, buffers, and other small
- 35 molecules, especially molecules having a molecular weight of less than 1000, can be present).

Once the appropriate coding sequence is isolated, it can be

SUBSTITUTE SHEET (RULE 26)

expressed in a variety of different expression systems; for example those used with mammalian cells, baculoviruses, bacteria, and yeast.

5 i. Mammalian Systems

Mammalian expression systems are known in the art. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3')
10 transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30
15 base pairs (bp) upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, usually located within 100 to 200 bp upstream of the TATA
20 box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation [Sambrook et al. (1989) "Expression of Cloned Genes in Mammalian Cells." In Molecular Cloning: A Laboratory Manual, 2nd ed.].

25 Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad
30 MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallothionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible), depending on the promoter can be
35 induced with glucocorticoid in hormone-responsive cells.

The presence of an enhancer element (enhancer), combined with the promoter elements described above, will usually

increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers
5 are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter [Maniatis et al. (1987) Science 236:1237; Alberts et al. (1989) Molecular Biology of
10 the Cell, 2nd ed.]. Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer [Dijkema et al (1985) EMBO J. 4:761] and the enhancer/promoters derived from the long terminal repeat
15 (LTR) of the Rous Sarcoma Virus [Gorman et al. (1982b) Proc. Natl. Acad. Sci. 79:6777] and from human cytomegalovirus [Boshart et al. (1985) Cell 41:521]. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion
20 [Sassone-Corsi and Borelli (1986) Trends Genet. 2:215; Maniatis et al. (1987) Science 236:1237].

A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the
25 DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.

30

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign
35 protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodes a signal

peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian
5 cells.

Usually, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus,
10 together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation [Birnstiel et al. (1985) Cell 41:349; Proudfoot and Whitelaw (1988) "Termination and 3' end processing of
15 eukaryotic RNA. In Transcription and splicing (ed. B.D. Hames and D.M. Glover); Proudfoot (1989) Trends Biochem. Sci. 14:105]. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription
20 terminator/polyadenylation signals include those derived from SV40 [Sambrook et al (1989) "Expression of cloned genes in cultured mammalian cells." In Molecular Cloning: A Laboratory Manual].

25 Some genes may be expressed more efficiently when introns (also called intervening sequences) are present. Several cDNAs, however, have been efficiently expressed from vectors that lack splicing signals (also called splice donor and acceptor sites) [see e.g., Gething and Sambrook (1981)
30 Nature 293:620]. Introns are intervening noncoding sequences within a coding sequence that contain splice donor and acceptor sites. They are removed by a process called "splicing," following polyadenylation of the primary transcript [Nevins (1983) Annu. Rev. Biochem. 52:441; Green
35 (1986) Annu. Rev. Genet. 20:671; Padgett et al. (1986) Annu. Rev. Biochem. 55:1119; Krainer and Maniatis (1988) "RNA splicing." In Transcription and splicing (ed. B.D. Hames and D.M. Glover)].

Usually, the above described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression
5 constructs. Enhancers, introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable
10 maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing the replication systems of papovaviruses, such as SV40 [Gluzman (1981) Cell
15 23:175] or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replication systems,
20 thus allowing it to be maintained, for example, in mammalian cells for expression and in a procaryotic host for cloning and amplification. Examples of such mammalian-bacteria shuttle vectors include pMT2 [Kaufman et al. (1989) Mol. Cell. Biol. 9:946 and pHEBO [Shimizu et al. (1986) Mol.
25 Cell. Biol. 6:1074].

The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art
30 and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

35

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC),

SUBSTITUTE SHEET (RULE 26)

including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines.

5

ii. Baculovirus Systems

The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably
10 linked to the control elements within that vector. Vector construction employs techniques which are known in the art.

Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which
15 contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for
20 the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.

After inserting the DNA sequence encoding the protein into
25 the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expressed and recombinant plaques are identified and purified. Materials and methods
30 for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA ("MaxBac" kit). These techniques are generally known to those skilled in the art and fully described in Summers and Smith, Texas Agricultural
35 Experiment Station Bulletin No. 1555 (1987) (hereinafter "Summers and Smith").

Prior to inserting the DNA sequence encoding the protein

SUBSTITUTE SHEET (RULE 26)

into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an intermediate transplacement
5 construct (transfer vector). This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its own set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements. Intermediate
10 transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for
15 cloning and amplification.

Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also been
20 designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, Virology (1989) 17:31.

25 The plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) Ann. Rev. Microbiol., 42:177) and a procaryotic ampicillin-resistance (amp) gene and origin of replication for selection and propagation in E. coli.

30

Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription of a
35 coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually

SUBSTITUTE SHEET (RULE 26)

includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be
5 either regulated or constitutive.

Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene
10 encoding the viral polyhedron protein, Friesen et al., (1986) "The Regulation of Baculovirus Gene Expression," in: The Molecular Biology of Baculoviruses (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the p10 protein, Vlak et al., (1988), J. Gen.
15 Virol. 69:765.

DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988)
20 Gene, 73:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by insect cells, and the signals required for secretion and nuclear
25 accumulation also appear to be conserved between the invertebrate cells and vertebrate cells, leaders of non-insect origin, such as those derived from genes encoding human α -interferon, Maeda et al., (1985), Nature 315:592; human gastrin-releasing peptide, Lebacqz-Verheyden et al.,
30 (1988), Molec. Cell. Biol. 8:3129; human IL-2, Smith et al., (1985) Proc. Nat'l Acad. Sci. USA, 82:8404; mouse IL-3, (Miyajima et al., (1987) Gene 58:273; and human glucocerebrosidase, Martin et al. (1988) DNA, 7:99, can also be used to provide for secretion in insects.

35

A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good

SUBSTITUTE SHEET (RULE 26)

intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If
5 desired, methionine at the N-terminus may be cleaved from the mature protein by in vitro incubation with cyanogen bromide.

Alternatively, recombinant polyproteins or proteins which
10 are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment usually encodes a signal
15 peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum.

After insertion of the DNA sequence and/or the gene encoding
20 the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus -- usually by co-transfection. The promoter and transcription termination sequence of the construct will
25 usually comprise a 2-5kb section of the baculovirus genome. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summers and Smith supra; Ju et al. (1987); Smith et al., Mol. Cell. Biol. (1983) 3:2156; and Luckow and Summers
30 (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), Bioessays 4:91. The DNA sequence, when
35 cloned in place of the polyhedrin gene in the expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.

SUBSTITUTE SHEET (RULE 26)

The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses. An advantage of the expression system is a visual screen allowing recombinant viruses to be distinguished. The polyhedrin protein, which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15 μm in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. "Current Protocols in Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990); Summers and Smith, supra; Miller et al. (1989).

Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, inter alia: Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni (PCT Pub. No. WO 89/046699; Carbonell et al., (1985) J. Virol. 56:153; Wright (1986) Nature 321:718; Smith et al., (1983) Mol. Cell. Biol. 3:2156; and see generally, Fraser, et al. (1989) In Vitro Cell. Dev. Biol. 25:225).

Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell
5 culture technology is generally known to those skilled in the art. See, e.g., Summers and Smith supra.

The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable
10 maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under inducible control, the host may be grown to high density, and expression induced. Alternatively, where expression is constitutive, the product will be continuously expressed
15 into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, e.g., HPLC, affinity chromatography, ion exchange chromatography, etc.;
20 electrophoresis; density gradient centrifugation; solvent extraction, or the like. As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a
25 product which is at least substantially free of host debris, e.g., proteins, lipids and polysaccharides.

In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under
30 conditions which allow expression of the recombinant protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.

35

iii. Bacterial Systems

Bacterial expression techniques are known in the art. A

bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in *Escherichia coli* (*E. coli*) [Raibaud *et al.* (1984) *Annu. Rev. Genet.* 18:173]. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (*lac*) [Chang *et al.* (1977) *Nature* 198:1056], and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (*trp*) [Goeddel *et al.* (1980) *Nuc. Acids Res.* 8:4057; Yelverton *et al.* (1981) *Nucl. Acids Res.* 9:731; U.S. Patent No. 4,738,921; EPO Publ. Nos. 036 776 and 121 775]. The *g*-lactamase (*bla*) promoter system [Weissmann (1981) "The cloning of interferon and other mistakes." In *Interferon 3* (ed. I. Gresser)], bacteriophage lambda PL [Shimatake *et al.*

(1981) Nature 292:128] and T5 [U.S. Patent No. 4,689,406] promoter systems also provide useful promoter sequences.

In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter [U.S. Patent No. 4,551,433]. For example, the tac promoter is a hybrid trp-lac promoter comprised of both trp promoter and lac operon sequences that is regulated by the lac repressor [Amann et al. (1983) Gene 25:167; de Boer et al. (1983) Proc. Natl. Acad. Sci. 80:21]. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074]. In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an E. coli operator region (EPO Publ. No. 267 851).

In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In E. coli, the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon [Shine et al. (1975) Nature 254:34]. The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' end of E. coli 16S rRNA [Steitz et al. (1979) "Genetic signals and nucleotide sequences in messenger RNA."

SUBSTITUTE SHEET (RULE 26)

In Biological Regulation and Development: Gene Expression (ed. R.F. Goldberger)]. To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site [Sambrook et al. (1989) "Expression of cloned genes in *Escherichia coli*." In Molecular Cloning: A Laboratory Manual].

A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will
10 always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide or by either in vivo or in vitro incubation with a bacterial methionine N-terminal peptidase (EPO Publ.
15 No. 219 237).

Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is
20 fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expressed in bacteria. The resulting fusion protein
25 preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene [Nagai et al. (1984) Nature 309:810]. Fusion proteins can also be made with sequences from the lacZ [Jia et al. (1987) Gene 60:197], trpE [Allen et al. (1987) J. Biotechnol. 5:93; Makoff et al. (1989) J. Gen. Microbiol. 135:11], and Chey [EPO Publ. No. 324 647] genes. The DNA
30 sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made
35 with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign protein can be isolated

[Miller et al. (1989) Bio/Technology 7:698].

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria [U.S. Patent No. 4,336,336]. The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the foreign gene.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the E. coli outer membrane protein gene (ompA) [Masui et al. (1983), in: Experimental Manipulation of Gene Expression; Ghrayeb et al. (1984) EMBO J. 3:2437] and the E. coli alkaline phosphatase signal sequence (phoA) [Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212]. As an additional example, the signal sequence of the alpha-amylase gene from various Bacillus strains can be used to secrete heterologous proteins from B. subtilis [Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. No. 244 042].

Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include

SUBSTITUTE SHEET (RULE 26)

transcription termination sequences derived from genes with strong promoters, such as the trp gene in E. coli as well as other biosynthetic genes.

5 Usually, the above described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an
10 extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a procaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a
15 high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least
20 about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.

Alternatively, the expression constructs can be integrated
25 into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the
30 bacterial chromosome. For example, integrating vectors constructed with DNA from various Bacillus strains integrate into the Bacillus chromosome (EPO Publ. No. 127 328). Integrating vectors may also be comprised of bacteriophage or transposon sequences.

35 Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed.

Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [Davies et al. (1978) 5 Annu. Rev. Microbiol. 32:469]. Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above described components can be
10 put together in transformation vectors. Transformation vectors are usually comprised of a selectable market that is either maintained in a replicon or developed into an integrating vector, as described above.

15 Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, inter alia, the following bacteria: *Bacillus subtilis* [Palva et al. (1982) 20 Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541], *Escherichia coli* [Shimatake et al. (1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et al. (1986) J. Mol. Biol. 189:113; EPO Publ. Nos. 036 776, 136 829 and 136
25 907], *Streptococcus cremoris* [Powell et al. (1988) Appl. Environ. Microbiol. 54:655]; *Streptococcus lividans* [Powell et al. (1988) Appl. Environ. Microbiol. 54:655], *Streptomyces lividans* [U.S. Patent No. 4,745,056].

30 Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with CaCl_2 or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation.

35 Transformation procedures usually vary with the bacterial species to be transformed. See .g., [Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036 259 and 063

- 953; PCT Publ. No. WO 84/04541, Bacillus], [Miller et al. (1988) Proc. Natl. Acad. Sci. 85:856; Wang et al. (1990) J. Bacteriol. 172:949, Campylobacter], [Cohen et al. (1973) Proc. Natl. Acad. Sci. 69:2110; Dower et al. (1988) Nucleic
5 Acids Res. 16:6127; Kushner (1978) "An improved method for transformation of Escherichia coli with ColE1-derived plasmids. In Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering (eds. H.W. Boyer and S. Nicosia); Mandel et al. (1970) J. Mol. Biol.
10 53:159; Taketo (1988) Biochim. Biophys. Acta 949:318; Escherichia], [Chassy et al. (1987) FEMS Microbiol. Lett. 44:173 Lactobacillus]; [Fiedler et al. (1988) Anal. Biochem 170:38, Pseudomonas]; [Augustin et al. (1990) FEMS Microbiol. Lett. 66:203, Staphylococcus], [Barany et al.
15 (1980) J. Bacteriol. 144:698; Harlander (1987) "Transformation of Streptococcus lactis by electroporation, in: Streptococcal Genetics (ed. J. Ferretti and R. Curtiss III); Perry et al. (1981) Infec. Immun. 32:1295; Powell et al. (1988) Appl. Environ. Microbiol. 54:655; Somkuti et al.
20 (1987) Proc. 4th Evr. Cong. Biotechnology 1:412, Streptococcus].

iv. Yeast Expression

- 25 Yeast expression systems are also known to one of ordinary skill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a
30 transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second
35 domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated

expression may be either positive or negative, thereby either enhancing or reducing transcription.

Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (EPO Publ. No. 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO Publ. No. 329 203). The yeast PHO5 gene, encoding acid phosphatase, also provides useful promoter sequences [Myanohara et al. (1983) Proc. Natl. Acad. Sci. USA 80:1].

In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. Patent Nos. 4,876,197 and 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, OR PHO5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (EPO Publ. No. 164 556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, inter alia, [Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979) "The Expression of Bacterial Antibiotic Resistance Genes i the Yeast *Saccharomyces cerevisiae*," in: Plasmids of Medical, Environmental and

Commercial Importance (eds. K>N> Timmis and A. Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et al. (1980) Curr. Genet. 2:109;].

- 5 A DNA molecule may be expressed intracellularly in yeast. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If
10 desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.

- Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, baculovirus, and bacterial
15 expression systems. Usually, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For
20 example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., EPO Publ. No. 196 056. Another example is
25 a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can
30 be isolated (see, e.g., PCT Publ. No. WO 88/024066).

- Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader
35 sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader

sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.

5 DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (EPO Publ. No. 012 873; JPO Publ. No. 62,096,086) and the A-factor gene (U.S. Patent No. 4,588,684). Alternatively, leaders of non-yeast origin,
10 such as an interferon leader, exist that also provide for secretion in yeast (EPO Publ. No. 060 057).

A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains
15 both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. Patent Nos.
20 4,546,083 and 4,870,008; EPO Publ. No. 324 274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alphafactor. (See e.g., PCT Publ. No.
25 WO 89/02463.)

Usually, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the
30 coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.

35 Usually, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together

into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two
5 replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a procaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 [Botstein *et al.* (1979) *Gene* 8:17-24], pCl/1 [Brake *et al.* (1984) *Proc. Natl.*
10 *Acad. Sci USA* 81:4642-4646], and YRp17 [Stinchcomb *et al.* (1982) *J. Mol. Biol.* 158:157]. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about
15 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See e.g., Brake *et al.*, *supra*.
20
Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to
25 integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome [Orr-Weaver *et al.* (1983) *Methods in Enzymol.* 101:228-245]. An integrating vector may
30 be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver *et al.*, *supra*. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced [Rine *et al.* (1983) *Proc. Natl.*
35 *Acad. Sci. USA* 80:6750]. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in

SUBSTITUTE SHEET (RULE 26)

the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.

5 Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as ADE2, HIS4, LEU2,
10 TRP1, and ALG7, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the
15 presence of CUP1 allows yeast to grow in the presence of copper ions [Butt et al. (1987) Microbiol. Rev. 51:351].

Alternatively, some of the above described components can be put together into transformation vectors. Transformation
20 vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either
25 extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, inter alia, the following yeasts: Candida albicans [Kurtz, et al. (1986) Mol. Cell. Biol. 6:142], Candida maltose [Kunze, et al. (1985) J. Basic Microbiol. 25:141], Hansenula polymorpha [Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302], Kluyveromyces fragilis [Das, et al. (1984) J. Bacteriol. 158:1165], Kluyveromyces lactis [De Louvencourt et al. (1983) J. Bacteriol. 154:737;
30 Van den Berg et al. (1990) Bio/Technology 8:135], Pichia guillermondii [Kunze et al. (1985) J. Basic Microbiol. 25:141], Pichia pastoris [Cregg, et al. (1985) Mol. Cell. Biol. 5:3376; U.S. Patent Nos. 4,837,148 and 4,929,555],

Saccharomyces cerevisiae [Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163], *Schizosaccharomyces pombe* [Beach and Nurse (1981) Nature 300:706], and *Yarrowia lipolytica* [Davidow, et al. 5 (1985) Curr. Genet. 10:380471 Gaillardin, et al. (1985) Curr. Genet. 10:49].

Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the 10 transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See e.g., [Kurtz et al. (1986) Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol. 25:141; Candida]; [Gleeson 15 et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302; Hansenula]; [Das et al. (1984) J. Bacteriol. 158:1165; De Louvencourt et al. (1983) J. Bacteriol. 154:1165; Van den Berg et al. (1990) Bio/Technology 8:135; Kluyveromyces]; [Cregg et al. (1985) 20 Mol. Cell. Biol. 5:3376; Kunze et al. (1985) J. Basic Microbiol. 25:141; U.S. Patent Nos. 4,837,148 and 4,929,555; Pichia]; [Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163 *Saccharomyces*]; [Beach and Nurse (1981) Nature 300:706; 25 *Schizosaccharomyces*]; [Davidow et al. (1985) Curr. Genet. 10:39; Gaillardin et al. (1985) Curr. Genet. 10:49; *Yarrowia*].

1. Preparation of LT mutants

30

1.1. Source of LT DNA

The 2kb *Sma*I-HindIII fragment from plasmid pEWD299, containing the LT genes and the LT promoter region (Pronk et al., 1985; Spicer et al., 1981), was subcloned into the 35 Blue-Script KS vector (Stratagene, San Diego, CA) generating the BS-LT and was used in all subsequent studies.

SUBSTITUTE SHEET (RULE 26)

1.2. Methods of mutation

Site-directed mutagenesis was performed on single-stranded DNA, using the method of Zoller and Smith (Zoller and Smith, 5 1982). To introduce the G192 mutation, using the following oligonucleotide :

5'-AATTCATCAGGCACAATCACA-3'

10 was used. Single-stranded DNA from BS-LT and BS-LTK63 plasmids, containing the wild-type and the mutated 1.3kb SmaI-EcoRI fragment, respectively, were used to perform site-directed mutagenesis with G192-oligonucleotide. DNA manipulations were performed by standard procedures 15 (Sambrook et al., 1989).

1.3. Expression and purification of the mutated coding region

20 LTG192 and LTK63/G192 mutants were purified from the periplasm of recombinant *E. coli* TG1 strains grown in a 20-liter fermentor. After centrifugation and sonication of the bacterial pellet, the purification was performed using CPG 350 (Controlled Pore Glass) (Sigma and Electronucleonics, 25 St. Louis, USA), A5M Agarose (Biorad, Richmond, USA) and Sephacryl S-200 (Pharmacia, Uppsala, Sweden) columns, as described by Pronk et al. (Pronk et al., 1985). Purified proteins with a concentration ranging from 0.44 to 1.5 mg/ml were stored at 4°C in the buffer TEAN pH7.5.

30

2. Preparation of CT mutants

2.1. Source of CT DNA

35 The 1.1 kb fragment of pJM17 plasmid (Pearson, G. D. N., et al., 1982) , containing the ctxAB gene, was amplified by PCR technique using the following oligonucleotides:

5' - GGCAGATTCTAGACCTCCTGATGAAATAAA - 3' (ctxA)

and

5' - TGAAGTTTGGCGAAGCTTCTTAATTTGCCATACTAATTGCG - 3' (ctxB).

The amplified XbaI-HindIII fragment was subcloned in pEMBL 19 vector (Dente, L., et al. 1983) and used for site-directed mutagenesis (Zoller, M. J., et al. 1982).

10

2.2. Methods of mutation

Single-stranded DNA of pEMBL 19-CT K63 plasmid, containing the 1.1kb XbaI-HindIII fragment, mutated in position 63, was used to perform site-directed mutagenesis with G192 oligonucleotide: AATGCTCCAGGCTCATCGATG.

15

2.3. Expression of the mutated coding region

The mutated XbaI-HindIII fragment containing the two mutations (Ser63->Lys, Arg192->Gly) was subcloned under the control of CT promoter into pGEM-3 vector (Promega, Madison, USA), generating the pGEM-CTK63/G192. *E. Coli* TG1 and *V. Cholerae* O395-NT strains were transformed by electroporation (Sambrook, J., et al. 1989) with pGEM-CTK63/G192 plasmid. The mutant protein CTK63/G192 was expressed into the periplasm of *E. Coli* strain and into the culture supernatant of *V. Cholerae* strain. The periplasmic extract of *E. Coli* were prepared as described (Pizza M., et al. 1990).

25

30

3. Properties of LT mutants

3.1. Toxicity test

35 *Toxin activity on Y1 cells.* The morphological change caused by LT on Y1 adrenal cells (Donta, S.T. et al., 1973) was used to detect the toxic activity of LT and LTG192 and LTK63/G192 mutants. The assay is was performed in microtiter

SUBSTITUTE SHEET (RULE 26)

plates using 50,000 cells/well. The results were read after 48hr of incubation. The assay detected 5 pg/well of wild type toxin. The LTG192 mutant was toxic at 12pg/well, the double mutant LTK63/G192 was non toxic at 11 µg.

5

Rabbit ileal Loop assay. New Zealand adult rabbits (ca. 2.5 kg) were used for the assay. The rabbits were starved for 24 hrs before the experiment. Before the operation, the rabbits were anaesthetized and fixed on the operation table. The 10 abdomen of the rabbit was opened with a scalpel and the intestine was extracted. The caecum was searched and 20-30 cm from this tract of intestine, 12-14 loops were made (each 5-6 cm in length) up to the approximative end of the intestine towards the stomach. 1ml of the sample was 15 injected into the loop and then the abdomen was closed.

After 18-20 hrs, the liquid accumulated in the loop was collected and measured with a syringe. The length of the loop was measured again. The results were expressed as liquid volume in loop length (ml/cm).

20

3.2. Immunogenicity tests

The mucosal immunogenicity of LTK63 and LTK63/G192 was tested by immunizing four mice intranasally (i.n.) with 1µg 25 of LT K63 and LT K63/G192, respectively. For i.n. immunizations, proteins were resuspended in phosphate-buffered saline (pH7.2; PBS) and delivered in a volume of 30µl (15µl/nostril). All the animals were immunized on days 1, 22, 36 and responses were followed by test sample 30 bleedings collect at days 0, 21 and 35. Mice were terminally bled on day 56.

Toxin-specific antibodies were measured using a GM1 capture ELISA. Antitoxin levels were estimated against the 35 homologous antigen used in the immunization. The plates were coated with 100µl/well of 1.5µg/ml GM1 ganglioside (Sigma Chemical Co., St. Louis, USA) at 4°C overnight. Plates were washed three times with PBS, 0.05% Tween 20 (PBS/T). 200

5 μ l/well of 1% BSA were added and the plates were incubated for 1 hour at 37°C. 100 μ l/well of the antigen were added and incubated overnight at 4°C. The sera of each mouse was added to each well starting from a dilution of 1:50 and subsequently 1:2 dilutions; serum samples were incubated for 2 hours at 37°C. Plates were washed as described above and incubated with anti-mouse immunoglobulin G conjugated to alkaline phosphatase (Sigma). After three washes, the substrate of alkaline phosphatase (pNPP) was added and the absorbancies were read at 450nm. ELISA titers were determined arbitrarily as the dilution corresponding to OD450=0.3.

3.3. Stability test

15

Trypsin treatment of LT and LT mutants. 60 μ g of LT and of each mutant were treated with 0.60 μ g of trypsin (Sigma, St. Louis, USA) (molar rate 100/1), in 300 μ l final volume of TEAN pH7.5 (non denaturing conditions) or TEAN pH7.5+3.5M urea (denaturing conditions) at 37°C. Samples of 30 μ l were collected at 0, 15, 30, 90 minutes (in non denaturing conditions) or 0, 5, 15, 30, 45, 60 minutes (in denaturing conditions) and the reaction stopped by addition of 10 μ l of 4x electrophoresis sample buffer (20% dithiothreitol, Bio Rad Richmond, USA; 8% sodiumdodecylsulfate, Bio Rad, Richmond, USA; 40% glycerol RPE-ACS, Carlo Erba, Milan, Italy; 0.02% bromophenolblue, Bio Rad, Richmond, USA; in Tris/HCl 0.25M pH6.8, Sigma, St.Louis, USA) and heating to 95°C for 5 minutes. The samples were run on 15% SDS-PAGE minigels and analysed by western blotting (Towbin et al., 1979 using rabbit anti-LT polyclonal antibody at a dilution of 1/300.

25

30

3.4. Conclusions

35

The results of the toxicity tests show that:

12 pg of the single mutant LTG192 are able to induce a toxic

effect on Y1 cells, while 11 μ g of the double mutant LTK63/G192 do not.

50ng of LTG192 are able to induce a fluid accumulation in
5 the intestinal loop of rabbits, while 100 μ g of the double mutant do not.

In terms of immunogenicity, the titer of the anti toxin
response in mice immunized with LTK63/G192 are greater than
10 those observed in mice immunized with LTK63.

The double mutant LTK63/G192 is more resistant to
proteolysis than the single mutant LT K63. The A subunit of
LT and LTK63 is completely processed in A₁ and A₂ after 15
15 minutes of incubation with trypsin. The A subunit of LTG192
and LTK63/G192 is resistant to the trypsin at least after
90 minutes of incubation. Moreover, the A subunit of LTK63
is completely degraded after 60 minutes of incubation with
trypsin in denaturing condition, while the A subunits of
20 LTG192 and LTK63/G192 has been only partially digested after
60 minutes of incubation with trypsin in denaturing
condition.

4. Properties of CT mutants

25

4.1. Stability test

Trypsin treatment. 50 μ l of periplasmic extract of *E. Coli*
strain containing the CTK63/G192 mutant was treated with
30 13.5 μ g/ml of trypsin at 37° C for 15 min. After incubation
at the sample were added of 4x loading buffer to stop the
reaction.

30 μ l of *V. Cholerae* culture supernatant and 30 μ l of
35 periplasmic extract of *E. Coli* treated with trypsin and
untreated were loaded on 15 % SDS-Polyacrylamide gel and the
proteins were transferred on nitrocellulose membrane to
perform a Western blotting.

4.2. Conclusions

The results show that both the single mutant CTN192 and the 5 double mutant CTK63/G192, are more resistant to proteases than the wild-type toxin. However, these mutants are still processed by the *V.cholerae* specific protease.

SUBSTITUTE SHEET (RULE 26)

References

- 5 Dente, L., G. Cesareni, and R. Cortese. 1983. pEMBL: a new family of single stranded plasmid. *Nucleic. Acid. Res.* **11**: 1645-1655
- 10 Donta, S.T., H.W. Moon and S.C. Whipp. 1973. Detection and use of heat-labile *Escherichia coli* enterotoxin with the use of adrenal cells in tissue culture. *Science (Wash.DC)*. **183**:334
- 15 Pearson, G. D. N., and J. J. Mekalanos. 1982. Molecular cloning of *Vibrio cholerae* enterotoxin gene in *Escherichia coli* K-12. *Proc. Natl. Acad. Sci. USA.* **79**: 2976-2980.
- Pizza, M., A. Covacci, M. Bugnoli, R. Manetti and R. Rappuoli. 1990. The S1 subunit is important for pertussis toxin secretion. *J. Biol. Chem.* **265**:17759-17763.
- 20 Pronk, S. E., H. Hofstra, H. Groendijk, J. Kingma, M. B. A. Swarte, F. Dorner, J. Drenth, W. G. J. Hol and B. Witholt. 1985. Heat-labile enterotoxin of *Escherichia coli*: characterization of different crystal forms. *J. Biol. Chem.* **260**:13580.
- 25 Sambrook, J., E.F. Fritsch and T. Maniatis. 1989. *Molecular cloning. A laboratory manual.* Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- 30 Spicer, E. K., W. M. Kavanaugh, W. S. Dallas, S. Falkow, W. Konigsberg and D. Shafer. 1981. Sequence homologies between A subunits of *E.coli* and *V.cholerae* enterotoxins. *Proc. Natl. Acad. Sci. USA.* **78**:50.
- 35 Zoller, M. J. and M. Smith. 1982. Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA. *Nucleic Acids Res.* **10**:6487.

CLAIMS:

1. An immunogenic detoxified protein comprising the amino acid sequence of subunit A of a cholera toxin (CT-A) or a
5 fragment thereof or the amino acid sequence of subunit A of an *Escherichia coli* heat labile toxin (LT-A) or a fragment thereof wherein the amino acids at, or in positions corresponding to, Ser-63 and Arg-192 are replaced with another amino acid.
- 10 2. A vaccine composition comprising an immunogenic detoxified protein according to claim 2 and a pharmaceutically acceptable carrier.
- 15 3. A vaccine composition according to claim 2 further comprising an adjuvant.
4. A vaccine composition according to claim 2 further containing a second immunogenic antigen.
- 20 5. A DNA sequence encoding an immunogenic detoxified protein according to claim 1.
6. A vector carrying a DNA according to claim 5.
- 25 7. A host cell line transformed with the vector according to claim 6.
8. A process for the production of an immunogenic
30 detoxified protein according to any one of claim 1 comprising culturing a host cell according to claim 7.
9. A process for the production of a DNA according to claim 5 comprising the steps of subjecting a DNA encoding
35 a CT-A or an LT-A or a fragment thereof to site-directed mutagenesis.
10. A method of vaccinating a mammal against *Vibrio*

SUBSTITUTE SHEET (RULE 26)

cholerae or an enterotoxigenic strain of *Escherichia coli* comprising administering an immunologically effective amount of an immunogenic detoxified protein according to claim 1.

5

11. A method for the prevention or treatment of disease in a subject comprising administering to the subject an immunologically effective dose of a composition according to claim 4.

10

12. A process for the formulation of a vaccine according to claim 2 comprising bringing an immunogenic detoxified protein according to claim 1 into association with a pharmaceutically acceptable carrier.

15

13. A process for the formulation of a vaccine according to claim 3 comprising bringing an immunogenic detoxified protein according to claim 1 into association with an adjuvant.

20

14. A process for the formulation of a vaccine according to claim 4 comprising bringing an immunogenic detoxified protein according to claim 1 into association with a second antigen.

SUBSTITUTE SHEET (RULE 26)

1 / 6

FIG. 1





FIG. 6



SUBSTITUTE SHEET (RULE 26)

2 / 6

FIG. 2A





FIG. 2B



SUBSTITUTE SHEET (RULE 26)

3 / 6

FIG. 3A






FIG. 3B



SUBSTITUTE SHEET (RULE 26)

4/6

FIG. 3C



SUBSTITUTE SHEET (RULE 26)

5 / 6

FIG. 4





FIG. 5



SUBSTITUTE SHEET (RULE 26)

6 / 6




FIG. 7

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

National Application No.

PC1/IB 96/00703

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/31 A61K39/106 C07K14/28 C07K14/245

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 13202 (BIOCINE SCLAVO SPA) 8 July 1993 cited in the application see page 6, line 8 - page 7, line 17; claims 1-14	1-14
Y	--- INFECTION AND IMMUNITY, vol. 62, no. 10, October 1994, WASHINGTON US, pages 4270-4278, XP002019077 C.C.R.GRANT ET AL.: "Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotoxic activities of Escherichia coli heat-labile enterotoxin" see page 4276, right-hand column --- -/--	1-14

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

21 November 1996

Date of mailing of the international search report

06.12.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

International Application No
PC., IB 96/00703

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	INFECTION AND IMMUNITY, vol. 63, no. 6, June 1995, WASHINGTON US, pages 2356-2360, XP002019078 M.R.FONTANA ET AL.: "Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit" see page 2356, right-hand column -----	1-14

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 96/00703

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 10 and 11
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 96/00703

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9313202	08-07-93	IT-B- 1253009	10-07-95
		AU-A- 3347693	28-07-93
		CA-A- 2127091	08-07-93
		EP-A- 0620850	26-10-94
		JP-T- 7506240	13-07-95

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.